Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAL - biologic dose titration in severe asthma
2020-003358-63Phase 4Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of mepolizumab, benralizumab and reslizumab in severe asthma and eosinophilic asthma (EA) (2 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Started Jul 2020; status: completed.
02
Drugs
mepolizumabbenralizumabreslizumab
03
Conditions
severe asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on 2020-003358-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003358-63.